Axsome Therapeutics, Inc. is a commercial-stage biopharmaceutical company specializing in the development and commercialization of innovative therapies for central nervous system (CNS) disorders. The ... Axsome Therapeutics, Inc. is a commercial-stage biopharmaceutical company specializing in the development and commercialization of innovative therapies for central nervous system (CNS) disorders. The company focuses on addressing medical conditions with significant unmet needs, offering treatments where existing options are limited or inadequate. Among its key marketed products are Auvelity, an oral medication for major depressive disorder, and Sunosi, for managing excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea. Axsome’s pipeline includes investigational therapies aimed at conditions such as Alzheimer’s disease agitation and migraine. By leveraging differentiated drug mechanisms and pursuing regulatory strategies that accelerate development, Axsome plays a crucial role in expanding treatment horizons for patients affected by CNS diseases. The company is noted for its robust intellectual property strategy and a management team with deep expertise in pharmaceutical development, underpinning its impact within the pharmaceuticals sector and its relevance in advancing CNS-focused therapeutic innovation.Show lessShow more

Disclosures ESG Data Financial Data

GHG Emissions Climate Targets EU Taxonomy Energy Waste Management

Data not available

No Climate Targets data disclosed by Axsome Therapeutics

We reviewed Axsome Therapeutics's website and available disclosure materials for the 2023 reporting period and did not identify any reported Climate Targets data.

If you would like us to review newly published materials or reassess the most recent disclosures, you can submit a data update request.

Would you like us to review Axsome Therapeutics's data?

Create a free Tracenable account to signal interest in having our team review data for Axsome Therapeutics.

Legal Center Contact Us